<DOC>
	<DOCNO>NCT02264873</DOCNO>
	<brief_summary>Decitabine hypomethylating agent show significant anti-leukemic effect Myelodysplastic Syndrome ( MDS ) Acute Myeloblastic Leukemia ( AML ) . This study base hypothesis Decitabine deliver allo-hematopoietic stem cell transplant ( HSCT ) patient leukemia enhance disease control allogeneic immune system lead long disease free survival . The study design provide safety data low-dosing post-transplant setting .</brief_summary>
	<brief_title>Phase I , Dose Escalation Study Decitabine</brief_title>
	<detailed_description>Decitabine hypomethylating agent significant anti-leukemic effect MDS AML . Additionally , aberrant DNA methylation identify high risk childhood ALL , therefore , DNA hypomethylating agent , decitabine , identify therapeutic agent . Moreover , decitabine immunomodulatory effect enhancement class I human leukocyte antigen ( HLA ) antigen expression cancer cell , increase susceptibility immune surveillance mechanism , graft-versus-leukemia effect donor cell allogeneic transplantation augmentation natural killer ( NK ) , T B lymphocyte reactivity . We hypothesize decitabine deliver allo-HSCT patient leukemia enhance disease control allogeneic immune system lead long disease free survival . However , safety study need determine appropriate decitabine dose post-transplant period . Low dos decitabine likely well tolerate post-transplant set give risk myelosuppression . In addition , administer low dos , decitabine 's hypomethylation effect pronounce relation pyrimidine analog cytotoxic effect . In study low dos decitabine administer begin 6 week 100 day post-transplant . Measures gene methylation immune reconstitution conduct define biologically active dos . Results trial provide new clinical data regard effect decitabine gene methylation immunoreactivity , establish maximally tolerate dose post-transplant setting , define biologically active dos , serve basis future efficacy trial .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age : great 1 less 31 year age ; Diagnosis : history ALL , AML MDS , currently complete remission ( CR ) follow alloHSCT ( bone marrow leukemic blast le 5 % morphology ) , high risk feature include : Status post allogeneic HSCT GVHD prophylaxis : Karnofsky Lansky performance score 50 % . Karnofsky score use patient &gt; 16 year age Lansky score patient ≤ 16 year age ; Platelet count ≥ 50,000 ( untransfused ) ; Absolute neutrophil count ≥ 1000 ; ; Hemoglobin ≥ 8 g/dL ( untransfused ) ; Progressive disease ; Philadelphia chromosome positive ALL ( patient receive tyrosine kinase inhibitor posttransplant ) ; Known hypersensitivity component decitabine ; Uncontrolled grade 34 graft versus host disease ; Uncontrolled infection ; Serum creatinine &gt; 2 mg/dL glomerular filtration rate ( GFR ) less 60 mL/min/1.73m2 ; Alanine Aminotransferase ( ALT ) great 3 time normal serum total bilirubin great 2 mg/dL ;</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Autologous stem cell transplant</keyword>
</DOC>